A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT

被引：0
|
作者：
Jingtao Gao
Mengqiu Gao
Jian Du
Yu Pang
Gary Mao
Nacer Lounis
Nyasha Bakare
Yanxin Jiang
Ying Zhan
Yuhong Liu
Liang Li
机构：
[1] Beijing Chest Hospital,Clinical Center On TB
[2] Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute,Department of Tuberculosis
[3] Beijing Chest Hospital,Department of Bacteriology and Immunology
[4] Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute,undefined
[5] Beijing Chest Hospital,undefined
[6] Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute,undefined
[7] Janssen Global Public Health,undefined
[8] Janssen Research & Development,undefined
[9] Janssen Pharmaceutica,undefined
[10] Janssen China Research & Development,undefined
[11] Innovation Alliance On Tuberculosis Diagnosis and Treatment (Beijing) [IATB],undefined
来源：
Trials | / 25卷
关键词：
Tuberculosis; Bedaquiline; China; Oral Short-course regimen;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 30 条
  • [1] A pragmatic randomized controlled trial to evaluate the efficacy and safety of an oral short-course regimen including bedaquiline for the treatment of patients with multidrug-resistant tuberculosis in China: study protocol for PROSPECT
    Gao, Jingtao
    Gao, Mengqiu
    Du, Jian
    Pang, Yu
    Mao, Gary
    Lounis, Nacer
    Bakare, Nyasha
    Jiang, Yanxin
    Zhan, Ying
    Liu, Yuhong
    Li, Liang
    TRIALS, 2024, 25 (01)
  • [2] New All-Oral Short-term Regimen for Multidrug-Resistant Tuberculosis: A Semi-randomized Controlled Trial Conducted in China
    Jing, Wei
    Wang, Qingfeng
    Wang, Jun
    Ma, Liping
    Huang, Mailing
    Wang, Jing
    Du, Yadong
    Cai, Baoyun
    Shi, Wenhui
    Li, Qi
    Li, Xuelian
    Chu, Naihui
    Nie, Wenjuan
    OPEN FORUM INFECTIOUS DISEASES, 2025, 12 (02):
  • [3] TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II–III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
    Catherine Berry
    Philipp du Cros
    Katherine Fielding
    Suzanne Gajewski
    Emil Kazounis
    Timothy D. McHugh
    Corinne Merle
    Ilaria Motta
    David A. J. Moore
    Bern-Thomas Nyang’wa
    Trials, 23
  • [4] Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China
    Du, Yadong
    Qiu, Chao
    Chen, Xiaohong
    Wang, Jing
    Jing, Wei
    Pan, Hongqiu
    Chen, Wei
    Liu, Yufeng
    Li, Chunxiang
    Xi, Xiu'e
    Yin, Hongyun
    Zeng, Jianfeng
    Zhang, Xia
    Xu, Tao
    Wang, Qingfeng
    Guo, Ru
    Wang, Jun
    Pang, Yu
    Chu, Naihui
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (04) : 1047 - 1054
  • [5] TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis
    Berry, Catherine
    du Cros, Philipp
    Fielding, Katherine
    Gajewski, Suzanne
    Kazounis, Emil
    McHugh, Timothy D.
    Merle, Corinne
    Motta, Ilaria
    Moore, David A. J.
    Nyang'wa, Bern-Thomas
    TRIALS, 2022, 23 (01)
  • [6] Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China
    Tang, Shenjie
    Yao, Lan
    Hao, Xiaohui
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [7] A non-randomized pragmatic historically controlled trial evaluating the effectiveness and safety of a bedaquiline or a linezolid-based short regimen for rifampicin-resistant tuberculosis
    Martinez-Camprecios, Joan
    Aznar, Maria Luisa
    Zacarias, Adriano
    Teran, Rafael
    Nindia, Arlete
    Espinosa-Pereiro, Juan
    Aixut, Sandra
    Ramos, Maria Eugenia
    Nicolau, Marcos Jose
    Sulleiro, Elena
    Tortola, Maria Teresa
    Sanchez-Montalva, Adrian
    Molina, Israel
    JOURNAL OF INFECTION, 2024, 89 (06)
  • [8] Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis
    Pai, Helen
    Ndjeka, Norbert
    Mbuagbaw, Lawrence
    Kaniga, Kone
    Birmingham, Eileen
    Mao, Gary
    Alquier, Lori
    Davis, Kourtney
    Bodard, Arianne
    Williams, Abeda
    Van Tongel, Magalie
    Thoret-Bauchet, Florence
    Omar, Shaheed, V
    Bakare, Nyasha
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [9] An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)
    Esmail, Aliasgar
    Oelofse, Suzette
    Lombard, Carl
    Perumal, Rubeshan
    Mbuthini, Linda
    Mahomed, Akhter Goolam
    Variava, Ebrahim
    Black, John
    Oluboyo, Patrick
    Gwentshu, Nelile
    Ngam, Eric
    Ackerman, Tertius
    Marais, Linde
    Mottay, Lynelle
    Meier, Stuart
    Pooran, Anil
    Tomasicchio, Michele
    Te Riele, Julian
    Derendinger, Brigitta
    Ndjeka, Norbert
    Maartens, Gary
    Warren, Robin
    Martinson, Neil
    Dheda, Keertan
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205 (10) : 1214 - 1227
  • [10] Efficacy and safety of the all-oral bedaquiline-containing regimen as treatment for pediatric multidrug/rifampicin-resistant tuberculosis: a multicenter, retrospective, cohort study
    Sun, Wen-Wen
    Yang, Ming
    Chen, Xiao-Hong
    Fan, Li-Chao
    Wu, Hao-Yu
    Zhang, Shao-Jun
    Chen, Yu
    Fan, Lin
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (04) : 219 - 227
123